CURRICULUM VITAE
`
`Douglas Reid Patterson, D.V.M., Ph.D.
`Diplomate: A.B.T., A.C.V.P., A.C.L.A.M.; Fellow: A.T.S., I.A.T.P.
`
`
`CURRENT POSITION: President, Reid Patterson Consulting, Inc.
`Email: reidpattersonconsulting@comcast.net, rpc-inc@comcast.net,
`or reidpatterson@comcast.net
`Cell: 239-398-6739
`Website: www.reidpattersonconsulting.com
`23620 Waterside Drive (Main & Winter Office 10/15-5/15)
`Bronita Springs, FL 34134-4905
`Phone: 239-676-9371
`W5210 Plantation Road (Summer Office 5/15-10/15)
`Elkhorn, WI 53121-3120
`Phone: 262-742-4998
`
`
`EDUCATION: Bachelor of Science (B.S.), Texas A&M University, l968
`
`Doctor of Veterinary Medicine (D.V.M.), Texas A&M U., l969
`
`Residency in Laboratory Animal Medicine, U. Mo., 1971-5
`
`Doctor of Philosophy (Ph.D.), U. of Missouri, l976
`
`30 hours toward M.B.A. (U. Houston & Northern Illinois)
`
`
`
`
`
`
`
`
`
`Diplomate, American College of Laboratory Animal Medicine, l976
`
`Diplomate, American College of Veterinary Pathologists, l978
`
`Diplomate, American Board of Toxicology, l98l
`
`Fellow, Academy of Toxicological Sciences, 2000
`
`Fellow, International Academy of Toxicologic Pathology, 2001
`
`
`SPECIALTY CERTIFICATION:
`
`
`
`
`
`
`SPECIALTY RECOGNITION:
`
`
`
`
`
`PROFESSIONAL EXPERIENCE:
`
`
`President, Reid Patterson Consulting, Inc.
`Divisional Vice President, Global Preclinical Safety, Abbott Laboratories
`Divisional Vice President, Drug Safety Evaluation, Abbott Laboratories
`Head, Neuroscience Venture, Abbott Laboratories
`
`
`Director, Division of Drug Safety Evaluation, Abbott Laboratories
`
`Director, Pathology/Toxicology, Abbott Laboratories
`
`
`Supervisor, Pathology, Teratology & Repro. Tox., Shell Development Co.
`Director, Department of Medicine, Hazleton Labs. America
`
`
`Head, Department of Pathology, Hazleton Labs. Europe
`
`
`Pathologist, Department of Pathology, Hazleton Labs. America
`
`Post-Doc. Fellow, Dept. Lab. Animal Med., U. Mo. Med. School
`
`Practitioner, Veterinary clinical practice, Houston, TX
`
`
`
`(2003-present)
`(2001-2003)
`(1991-2001)
`(1992-93)
`(1987-90)
`(1984-87)
`(1981-84)
`(1980-81)
`(1978-80)
`(1975-78)
`(1971-75)
`(1969-71)
`
`
`
`1
`
`INTELGENX 1008
`
`

`
`
`
`[D. Reid Patterson, D.V.M., Ph.D.]
`
`DETAILED PROFESSIONAL EXPERIENCE: PHARMACEUTICAL INDUSTRY
`
`President, Reid Patterson Consulting, Inc.,
`Pharmaceutical R&D consulting firm, Grayslake, IL 60030; Present Position (Jan. 2004 to present)
`
`Dr. Patterson elected to utilize his 40+ years of professional veterinary life, 35+ years as a toxicologic
`
`pathologist, 20 years as a pharmaceutical research and development (R&D) executive, and 12 years as a drug
`development consultant to assist and advise pharmaceutical and biotechnology firms in the successful development
`of therapeutics vital to society’s needs. During Dr. Patterson’s tenure at Abbott Laboratories, he participated in the
`development of drugs for acid reflux, AIDs, analgesia, anemia, anesthesia, asthma, benight prostatic hyperplasia and
`cancer, bipolar disorder, cancer, cardiovascular disorders, diabetes, depression, epilepsy, erectile dysfunction, fungal
`diseases, gastric motility, hepatic disease, hormone replacement therapy, immunosuppression, infectious disease,
`iron deficiency, lupus erythematosis, migrane headaches, obesity, pain management, pulmonary function, renal
`failure, rheumatoid arthritis, schitzophrenia, sedation, stents, surgical suturing, thromobses, urinary incontinence,
`viral diseases, and others. The targets have expanded during his consulting experience. He uses these experiences to
`assist firms in strategic planning, development program design, study design, placement and monitoring and in the
`assembly of scientific data into coherent submissions to global regulatory agencies. To date, Dr. Patterson supports
`over 50 pharmaceutical clients and makes regular presentations on their behalf.
`
`Divisional Vice President, Global Preclinical Safety
`Global Pharmaceutical R&D Division, Abbott Laboratories, Abbott Park, IL 60064-3500; Previous Position: (Jan.
`2001- Dec. 2003)
`
`
`Dr. Patterson had managerial and scientific responsibilities for the safety assessment of all drug candidates
`and other potential in vivo Abbott products throughout the world, plus provided research support in the drug
`discovery process. To accomplish these tasks, a team of multidiciplinary scientists generated data and reports
`describing drug absorption, distribution, metabolism, and excretion (ADME) in subhuman and human subjects and
`patients plus any associated toxicologic pathology in representative animal models. Ultrastructural and biochemical
`characterization of products and tissues through the use of electron microsocopy and cellular biological techniques
`was under his authority. The departments essential in these efforts included Experimental Kinetics and Analysis;
`Regulatory Toxicology & Safety Pharmacology; Pathology; Clinical Pathology; Comparative Medicine; Drug
`Analysis; Metabolism, Radiochemistry & Cellular Toxicity; and Cellular & Microscopic Research. The organization
`was composed of approximately 250 scientific personnel, including about 50 doctoral-level professionals under a
`budget of over $70MM.
`Dr. Patterson planed, organized, and directed the uses of manpower, facilities, materials, equipment and
`budgets of this division and its departments. He formulated departmental and divisional goals in light of corporate
`and divisional objectives, implemented divisional and corporate policies, assigned duties and functions and measured
`performance in terms of goals and commitments.
`Technical and administrative decisions, recommendations, and leadership were the responsibility of the
`Vice President. Problem solving of personnel, administrative and budgetary issues were his responsibility. The
`design, conduct, evaluation, interpretation and reporting of all safety assessments studies in a timely and cost-
`effective manner were critical to the Division's success. The Vice President served as a key resource in the
`presentation and scientific discussion of all safety (toxicity), metabolic and chemical data on potential and existing
`products to domestic and foreign regulatory bodies.
`Dr. Patterson acted as a resource on matters pertaining to personnel safety and serves on numerous
`corporate and divisional committees and task forces involved with issues vital to or of interest to the corporation,
`including his role as the Institutional Official and former Chairman of Abbott's Institutional Animal Care and Use
`Committee. The Vice President reported directly to a manager from the former Knoll organization, the Divisional
`Vice-President for Global Preclinical Drug Development of the Global Pharmaceutical R&D Division of Abbott
`Laboratories.
`
`
`
`2
`
`INTELGENX 1008
`
`

`
`[D. Reid Patterson, D.V.M., Ph.D.]
`
`Divisional Vice President, Drug Safety Evaluation
`GPRD, Abbott Laboratories, Abbott Park, IL 60064-6104
`Previous Position: (Jan. 1991-Jan. 2001)
`
`
`
`Dr. Patterson had the same responsibilities described above with the exception of 37 staff members in
`Germany obtained during the acquisition of Knoll (BASF) Pharmaceuticals. In 1995, Drug Safety Evaluation was
`comprised of approximately 400 scientific personnel, including over 120 doctoral-level scientists and an operating
`and capital budget of approximately $71MM. Up until November, 1995, the responsibility additionally included the
`Division of Analytical Research, comprised of the Departments of Structural Chemistry, Physical Analytical
`Chemistry, Bioanalytical Chemistry, Anti-Infective Analytical Research, and Protein Chemistry. This organization
`provided data on the chemical characterization, stability, and analytical methodologies for every new drug entity and
`is currently organized under a different Divisional VP for Pharmaceutical Analytical and Research Development.
`Up until December, 1999, his responsibility included Clinical Pharmacokinetics, a staff of approximately 20
`scientists; this organization was then merged with Clinical Pharmacology to create a new Division. In 2001, a
`Cellular and Molecular Toxicology team formed and trained in DSE was moved into the Discovery organization to
`be more directly supported and funded by their clients. Dr. Patterson reported to a Corporate Vice President for
`Research & Development, then later to a newly appointed Corporate Vice President for Development, during these
`10 years.
`
`Head, Neurotherapeutics Venture
`PPD, Abbott Laboratories, Abbott Park, IL 60064-3500
`Previous Position: (Aug., 1992 - Nov. 1993)
`
`
`Dr. Patterson had responsibility for the rapid and safe development of tiagabine hydrochloride, a novel anti-
`epileptic agent intended for the treatment of patients with partial seizures, including those with complex
`symptomatology with or without secondary generalized tonic-clonic seizures. Responsibilities included the creation
`of strategic plans, hiring key staff of the venture team, directing all activities from chemical production of bulk drug
`to performance of clinical trials, managing the financial resources, providing safe and ethical oversight, motivating
`and leading supporting technical specialists, and assuring regulatory compliance and understanding. With a
`professional staff of approximately 30 (4 doctoral level) and numerous contracted external professionals, Dr.
`Patterson managed the $20 million/annum program successfully from Phase II into Phase III and through the End-of-
`Phase II meeting with the FDA. He further had responsibility for and directed an extended team of supporting
`professionals in bulk drug synthesis, analytical research, formulation, metabolism, pharmacology, pharmacokinetics,
`toxicology, data management, statistics and numerous clinical support groups, including an external CRO. The
`position reported intially to the Vice President for Development, Pharmaceutical Products Division of Abbott
`Laboratories, but later reported into a Vice President for Immunoscience, Neuroscience, Cardiovascular and
`Thrombolytic Development. (This position was held concurrently with responsibilities as Vice President for Drug
`Safety Evaluation, with a combined responsibility for nearly 400 professional and technical staff and approximately
`$75MM in budget responsibility.)
`
`
`
`Director, Division of Drug Safety Evaluation
`PPD, Abbott Laboratories, Abbott Park, IL
`Previous Position: (July, l987 - Dec., 1990)
`
`
`Dr. Patterson's former responsibilities were similar to those mentioned above under DVP, DSE, except the
`scope of the responsibilities was somewhat less. His former position was expanded in 1987 to incorporate the
`Departments of Analytical Research, Drug Metabolism and Cellular and Microscopic Research (formerly known as
`Electron Microscopy). Thus, he began with a staff of 177 members and a budget of just under $20MM.
`
`
`
`3
`
`INTELGENX 1008
`
`

`
`[D. Reid Patterson, D.V.M., Ph.D.]
`
`Director, Pathology/Toxicology
`PPD, Abbott Laboratories, Abbott Park, IL
`Previous Position: (July, 1984 - July, 1987)
`
`
`In his initial position with Abbott, Dr. Patterson was responsible for the safety assessment of drug
`candidates and other potential Abbott products by the proper conductance and interpretation of animal safety and
`mutagenicity studies. The departments essential in these efforts were Toxicology, Pathology and Animal Health and
`Services, represented by over 75 scientific personnel and an operating budget of approximately $7MM. His general
`responsibilities were those described in his later positions, albeit without the chemistry and research arms currently
`within the Division.
`
`DETAILED PROFESSIONAL EXPERIENCE: PETROCHEMICAL INDUSTRY
`
`Supervisor - Pathology, Teratology and Reproductive Toxicology
`Department of Pathobiology, Toxicology Laboratory, Westhollow
`Research Center, Shell Development Company, Houston, Texas.
`Previous Position: (April, l98l - July, l984)
`
`
`Dr. Patterson's primary responsibilities related to laboratory operations management with particular
`emphasis on the development and administration of clinical and anatomic pathology services and the research efforts
`in teratology and reproductive toxicology at the Westhollow Research Center. He also supervised research and
`technical services provided to petroleum product business areas of the company and administered Toxicology's
`interaction in the American Petroleum Institute.
`Specific tasks included interpreting morphological responses to toxic injury in experimental animals to
`other scientists in Shell and at regulatory agencies and to business managers, designing, monitoring and reviewing
`toxicology studies, coordinating the workload within the clinical and anatomic pathology laboratories and between
`other laboratory groups, establishing and maintaining functional relationships with other laboratory groups and
`business centers, reviewing and approving study plans, reviewing protocols and reports, and assuring the timing and
`quality of the laboratory work in all areas of pathology and reproductive toxicology.
`He also had responsibility for the development and maintenance of standard laboratory operating procedure
`manuals, performance appraisals of professional and support staff, staff training and related documentation and
`maintenance of necessary skill levels and facilities within his group. Budgetary development and cost control were
`also within his charge. Finally, he was responsible for the maintenance of trained personnel knowledgeable in areas
`of pathology pertinent to Shell products and in the technical contribution of this knowledge and experience.
`Dr. Patterson also provided technical support to the Animal Resources group because of his co-
`specialization in laboratory animal medicine. He held an academic appointment as an adjunct Assistant Professor
`within the Department of Comparative Medicine, University of Texas Medical School at Houston until his departure
`from Texas in l984.
`
`DETAILED PROFESSIONAL EXPERIENCE: CONTRACT LABORATORY INDUSTRY
`
`Director, Department of Medicine
`Hazleton Laboratories America, Inc., Vienna, VA.
`Previous Position: (July, l980 - March, l98l)
`
`
`Dr. Patterson was principally responsible for the development and implementation of policies insuring the
`humane care and management of the numerous laboratory animal species used at Hazleton. Compliance with the
`Animal Welfare Act and its amendments, plus the Guide for the Care and Use of Laboratory Animals, produced by
`D.H.E.W. and implemented by A.A.A.L.A.C., was a major responsibility of the Department of Medicine and
`Hazleton's Animal Care Committee, both chaired by Dr. Patterson.
`
`
`
`4
`
`INTELGENX 1008
`
`

`
`[D. Reid Patterson, D.V.M., Ph.D.]
`
`
`Duties relating to laboratory animal care for which Dr. Patterson was responsible, included the development
`of company policies and standard procedures for animal handling and experimental use, monitoring and evaluating
`the animals' macro- and microenvironment for microbiological and chemical contaminants, assuring compliance with
`guidelines established by N.I.H., F.D.A., E.P.A. and A.A.A.L.A.C., approving all facility renovations and designs
`relating to animal care, evaluating animal, feed and bedding suppliers, certifying health status of experimental
`animals and selecting appropriate laboratory equipment.
`Dr. Patterson was also responsible for sampling and interpreting the contaminant analyses of food, water
`and bedding, coordinating a vermin control program, providing clinical services in ophthalmology, cardiology,
`neurology and radiology and developing and administering technician training programs. To accomplish these tasks,
`Dr. Patterson had both professional (D.V.M.) and technical staff in his department.
`As Director of the Department of Medicine, Dr. Patterson also supervised the Microbiology Laboratory,
`which provided support for internal studies, laboratory animal medicine, and external clients. Dr. Patterson
`principally worked with the Head of the Laboratory in areas of fiscal accountability, program development,
`marketing and personnel relations.
`Being a pathologist and scientist, Dr. Patterson had continued his involvement in histopathology and project
`management by participating in studies at Hazleton and by establishing a referral contract pathology service for
`external clients. Dr. Patterson was developing a new laboratory animal diagnostic service for animal producer and
`user laboratories.
`
`Head, Department of Pathology
`Hazleton Laboratories Europe Ltd., Harrogate, England.
`Previous Position: (June, l978 - July, l980)
`
`
`Dr. Patterson was singly responsible for the development and supervision of the Department of Pathology
`and for the coordination with other departments within the laboratories. These duties included scheduling,
`monitoring and performing or supervising the histopathologic interpretation of tissues from experiments using all
`the common laboratory animal species. Dr. Patterson was responsible for the procurement of new equipment, the
`review of experimental protocols, the training of new staff, the assurance of quality data, the authorship and updating
`of procedure manuals, plus the development and monitoring of annual budgets. Before being recalled to the
`American laboratories, Dr. Patterson hired 5 additional pathologists and established a contract pathology service,
`principally serving continental European clients.
`Dr. Patterson also served as principal investigator of several toxicology studies, provided needed
`interpretation of clinical pathology data in many other experiments and supervised the Head of Laboratory Animal
`Medicine. During his tenure, Dr. Patterson was successful in establishing a U.K./European Division of the Charles
`Louis Davis, D.V.M. Foundation for the Advancement of Veterinary Pathology, an American organization providing
`continuing education to veterinary, experimental and research pathologists.
`
`Staff/Senior Staff Pathologist
`Department of Pathology, Hazleton Laboratories America, Inc.,
`Vienna, VA. Previous Position: (Sept., l975 - June, l978)
`
`
`Dr. Patterson's principal responsibility was to provide macroscopic and microscopic description and
`interpretation of spontaneously occurring and experimentally induced pathological lesions in numerous laboratory
`animal species. In performing these duties, he compiled the data into incidence tables and interpreted their
`relationship to the experimental protocol. He also supervised necropsy procedures to insure proper description of
`gross observations, utilization of tissue preservatives, and handling and collection of required tissues.
`Dr. Patterson also participated as co- or principal investigator on experimental projects and in doing so was
`actively involved in the review of pertinent literature, experimental design, experiment implementation and data
`evaluation. He was actively involved in the clinical and pathological evaluation of the laboratory animals in support
`of the Director of Laboratory Animal Medicine. He taught portions of several courses in laboratory animal medicine
`and clinical pathology at Hazleton and in an area college.
`
`
`
`5
`
`INTELGENX 1008
`
`

`
`[D. Reid Patterson, D.V.M., Ph.D.]
`
`DETAILED PROFESSIONAL EXPERIENCE: PROFESSIONAL TRAINING AND DEVELOPMENT
`
`N.I.H. Postdoctoral Fellow in Laboratory Animal Medicine
`Department of Laboratory Animal Medicine, School of Medicine
`
`Research Associate
`Department of Veterinary Pathology
`School of Veterinary Medicine, University of Missouri,
`Columbia, MO. Previous Position: (Nov., l97l - Aug., l975)
`
`
`Dr. Patterson's residency program required two years of extensive clinical training in laboratory animal
`medicine, including seventeen credit hours of formal classroom training in the biology, husbandry, diseases and
`pathology of common laboratory species, plus additional courses in experimental surgery, statistics and experimental
`design. Dr. Patterson's research training occurred in the Department of Pathology at the medical school, where he
`investigated structural and functional changes in hepatic mitochondria during ketogenesis in both spontaneously and
`streptozotocin-induced diabetic rodents. The dissertation was entitled: Biochemical and Morphological Adaptation
`of Hepatic Mitochondria to Diabetes Mellitus. Utilized in these investigations were techniques of differential ultra-
`centrifugation, enzymology, polargraphy, radioimmuno-assay, light microscopy and serial section electron
`microscopy. The extensive training in veterinary, comparative and human pathology and the research activities
`enabled Dr. Patterson to obtain a Ph.D. in comparative pathology from the University.
`
`DETAILED PROFESSIONAL EXPERIENCE: PRIVATE VETERINARY PRACTICE
`
`Private Practice of Veterinary Medicine and Surgery
`Pet Clinics, Inc., Houston, TX
`Previous Position: (Sept., l969 - Nov., l97l)
`
`PUBLICATIONS (15):
`
`Clifford, D. H., Waddell, E. D., Patterson, D. R., Wilson, C. F., and Thompson, H. L.: Management of Esophageal
`Achalasia in Miniature Schnauzers. J. Am. Vet. Med. Assoc. l6l(9):l0l2-l02l, l972.
`
`Patterson, D. R., Wagner, J. E., Owens, Dr. R., Ronald, N. C. and Frisk, C. S.: Candida Albicans Infections in
`Spider Monkeys Following Antibiotics and Corticosteroid Therapy. J. Am. Vet. Med. Assoc. l64(7):72l-722, l974.
`
`Patterson, D. R.: Animal Models of Diabetes Mellitus. A Review. Lab. Animal l0(3):40-47, l98l.
`
`Parker, C. M., Patterson, D. R., Van Gelder, G. A., Gordon, E. B., Valerio, M. G. and Hall, W. C.: Chronic
`Toxicity and Carcinogenicity Evaluation of Fenvalerate in Rats. J. of Toxicol. Environ. Hlth. 13(1):83-97, 1984.
`
`Parker, C. M., Albert, J. R., Van Gelder, G. A., Patterson, D. R. and Taylor, J. L.: Neuropharmacologic and
`Neuropathologic Effects of Fenvalerate in Mice and Rats. Fundamental and Applied Toxicology 5(2):278-286,
`1985.
`
`Lu, C. C., Cagen, S. Z., Darmer, K. I., Jr., Patterson,D.R. and Chai, E. Y.: Testicular Effects Induced by Dermal or
`Inhalation Exposure to Para-Tertiary Butyl Benzoic Acid (ptBBA) in Fischer 344 Rats. J. Am. Coll. Toxicol.
`6(2):233-243, 1987.
`
`Patterson, D. R. (1991): Quinolone Toxicity: Methods of Assessment. Am. J. Med. 91(6A):35S-37S.
`
`Guay, D. R. P., Patterson, D. R., Seipman, N. and Craft, J. C. (1993): Overview of the Tolerability Profile of
`Clarithromycin in Preclinical and Clinical Trials. Drug Safety 8(5):350-364.
`
`
`
`
`6
`
`INTELGENX 1008
`
`

`
`[D. Reid Patterson, D.V.M., Ph.D.]
`
`PUBLICATIONS (continued):
`
`Lehrer, S.B., Tekeli, S., Fort, F.L., Cusick, P.K., Krasula, R.W. and Patterson, D.R. (1992): Effects of a GnRH
`agonist on fertility following administration to prepubertal male and female rats. Fund. Appl. Toxicol. 19(1):101-
`108.
`
`Fort, F.L., Ruckman, S.A., Gregson, A.L., and Patterson, D.R. (1993): Buflomedil: One-year oral safety evaluation
`in rats. Drug Chem. Toxicol. 16(2):195-205.
`
`Guay, D.R.P., Patterson, D.R., Seipman, N., and Craft, J.C. (1993): Overview of the Tolerability Profile of
`Clarithromycin in Preclinical and Clinical Trials. Drug Safety 8(5):350-364.
`
`Patterson, D.R., Hamlin, M.H., Hottendorf, G.H., Gough, A., Brown, W.R. (1995): Proliferative Lesions of the
`Adrenal Glands in Rats. In: Guides for Toxicologic Pathology. STP/ARP/AFIP, Washington, DC.
`
`Jolly R.A., Ciurlionis R., Morfitt D., Helgren M., Patterson R., Ulrich R. G., Waring J.F. (2004): Mirovesicular
`Steatosis Induced by a Short Chain Fatty Acid: Effects on Mitochondrial Function and Correlation with Gene
`Expression. Tox. Pathol. 32(S2):19-25.
`
`Cockerell GL, Patterson DR. (2005): Closing the supply versus gap for veterinary pathologists: a multifaceted
`problem in need of a multifaceted solution. Can Vet J 46(7):660-1.
`
`Cockerell GL, Patterson DR. (2005): Closing the supply versus gap for veterinary pathologists: a multifaceted
`problem in need of a multifaceted solution. Vet Clin Pathol 34(3):179-80.
`
`Cockerell GL, Patterson DR. (2005): Closing the supply versus gap for veterinary pathologists: a multifaceted
`problem in need of a multifaceted solution. Vet Pathol 42(4):403-4.
`
`Walzer M, Bekersky I, Wanaski S, Collins S, Jortner B, Patterson, R, Garman R, Sagar S, Tolbert D. (2011): Oral
`Toxicity of Vigabatrin in Immature Rats: Characterization of Intramyelinic Edema. NeuroToxicology 32(6):963-74.
`
`ABSTRACTS (25):
`
`Patterson, D. R.: Fatal Dysentery in Three Spider Monkeys. Eighth Annual Quad. Branch Meeting of the Am.
`Assoc. for Lab. Anim. Sci., Kansas City, MO, April 29, l973.
`
`Patterson, D. R.: Candida Albicans Infections in Spider Monkeys Following Antibiotics and Corticosteroid
`Therapy. Am. Vet. Med. Assoc. Annual Meeting, Philadelphia, PA, July l9, l973.
`
`Patterson, D. R.: Prophylactic Antibiotic Versus No Prophylactic Administration and Atgard Versus Equigard
`Comparisons as Disease Prevention Procedures in a Random Source Dog Colony. Ninth Annual Quad. Branch
`Meeting of Am. Assoc. for Lab. Anim. Sci., Columbia, MO, March l5, l974.
`
`Patterson, D. R.: Characterization of a Spontaneously Diabetic Animal Model, Mystromys albicaudatus. Seminar
`presented to Texas A&M University College of Veterinary Medicine, College Station, TX, Dec. l7, l974 and to the
`Department of Pathology, Baylor College of Medicine, Houston, TX, Dec. l9, l974.
`
`Patterson, D. R.: Biochemical and Morphological Adaptation of Hepatic Mitochondria to Diabetes Mellitus. Ph.D.
`Dissertation, University of Missouri, l975.
`
`Patterson, D. R.: Absolute Eosinophilia in Random Source Dogs During Quarantine Period. Tenth Annual Quad.
`Branch Meeting of Am. Assoc. for Lab. Anim. Sci., St. Louis, MO, March 2l, l975.
`
`
`
`7
`
`INTELGENX 1008
`
`

`
`
`[D. Reid Patterson, D.V.M., Ph.D.]
`ABSTRACTS (continued):
`
`Patterson, D. R.: Mycobacterium Kansasii Infection in Rhesus Monkeys. Am. Vet. Med. Assoc. Annual Meeting,
`Atlanta, GA, July l3, l977.
`
`Patterson, D. R.: What's Your Diagnosis Moderator, National Capital Area Branch of Am. Assoc. for Lab. Anim.
`Sci., Cockeysville, MD, Sept. l3-l4, l978.
`
`Patterson, D. R.: Toxicity and Pathology of N-Nitrosomethylurea (N.S.C. No. 23909) in Monkeys, Dogs and Mice
`Following Single Intravenous Administration. 2lst Congress of the European Society of Toxicology, Dresden, East
`Germany, June l2, l979.
`
`Patterson, D. R.: Animal Models of Diabetes Mellitus. Nat. Cap. Area Branch of Am. Assoc. for Lab. Anim. Sci.,
`Cockeysville, MD, Sept. 4, l980.
`
`Patterson, D. R.: Complex Hepatix Mitochondria: Location, Function and Adaptation to Disease. 3lst Annual
`Session of Am. Assoc. for Lab. Anim. Sci., Indianapolis, IN, Oct. l0, l980.
`
`Patterson, D. R.: Hepatocytic Changes Preceding Diabetes in Mystromys, 3lst Annual Session of Am. Assoc. for
`Lab. Anim. Sci., Indianapolis, IN, Oct. 7-8, l980.
`
`Patterson, D. R.: Comparative Pathology of Therapeutically-Equivalent Doses of Hypolipidemic Agents Fed to
`Rats. Toxicology Specialty Group Session at Annual meeting of the Am. College of Vet Pathologists, New Orleans,
`LA, Dec. 2, l980.
`
`Patterson, D. R.: Hepatic Neoplasia in Rats and Mice Gavaged with Selenium Sulfide for Two Years. CIIT
`Conference on Toxicology: Current Perspectives in Mouse Liver Neoplasia, Raleigh, NC, Dec. 3, l98l.
`
`Darmer, K. I., Jr., Cagen, S. Z., Patterson, D. R., Lu, C. C. and Gardiner, T. H.: The Toxicity of Para-Tertiary
`Butyl Benzoic Acid (ptBBA) in Rats Following 90-Day Dermal Application, Single 4-Hour Dust Inhalation and 7-
`Day Repeated Dust Inhalation. Gulf Coast Chapter, Society of Toxicology, Houston, TX, Oct. 2l, l983.
`
`Patterson, D. R.: Histology of Laboratory Rodents and Rabbits: Nervous, Endocrine, Integument and Sense
`Organs. American Assoc. for Lab. Animal Science, A.C.L.A.M./A.S.L.A.P. Co-sponsored Symposium, San
`Antonio, TX, Nov. l0, l983.
`
`Kimura, E. T., Tekeli, S., Patterson, D. R. and Kesterson, J. W.: Three-Month Oral Toxicity Study in Rats with
`Abbott-56234, a Uricosuric Diuretic. Corporate Technology Exchange Conference, Abbott Laboratories, Nov. 26,
`1985.
`
`Majors, K. R., Dudley, R. E., Tekeli, S., Buratto, B. and Patterson, D. R.: Toxicity of an Exogenous Surfactant
`Administered Intratracheally to Rats and Ferrets. 25th Annual Meeting of the Society of Toxicology, New Orleans,
`LA, March 3-7, 1986.
`
`Yang, C. L., Buratto, B., Lewkowski, J. P., Cusick, P. K., Patterson, D. R. and Kesterson, J. W.: Subchronic
`Toxicity of Calcitriol in Rats. 25th Annual Meeting of the Society of Toxicology, New Orleans, LA, March 3-7,
`1986.
`
`Cusick, P. K., Patterson, D. R., and Buratto, B.: Benign adrenal medullary tumors in a two-year combined chronic
`toxicity and carcinogenicity study of A-45975 (Terazosin) administered to rats in the diet. Poster at Society for
`Toxicologic Pathologist annual meeting, Boston, June 7, 1988.
`
`
`
`
`
`8
`
`INTELGENX 1008
`
`

`
`[D. Reid Patterson, D.V.M., Ph.D.]
`ABSTRACTS (continued):
`
`Weltman, R. H., Tekeli, S., Friedman, M. B., Krasula, M. B., Cusick, P. K. and Patterson, D. R.: Splanchnic
`Arterial Effects of the Dopamine Receptor Agonist ABBOTT-68979 in Rats. Poster presentation at the annual
`meeting of the Society of Toxicology, Miami, Feb. 13, 1990.
`
`Hui, J. Y., Diehl, M. S., Fort, F. L., Cusick, P. K., Krasula, R. W. and Patterson, D. R.: Development of the Fetal
`Mouse Palate in an In Vitro Culture System. Presented at the Annual Meeting of the Midwest Regional Chapter of
`the Society of Toxicology, May 10, 1991, Linchonshire, Illinois.
`
`Patterson, D. R.: Chemistry Considerations and the Role of Existing Pharmacology/Toxicology Data in the
`Planning of Rodent Tumorigenicity Studies; presented at DIA Conference entitled: Recent Considerations on the
`Design, Interpretation and Evaluation of Rodent Carcinogenicity Studies, Rockville, MD, Sept. 30 - Oct. 1, 1991;
`session moderator for session entitled: Preliminary Issues, Sept. 30, 1991.
`
`Hui, J. Y, Diehl, M. S., Fort, F. L., Cusick, P. K., Krasula, R. W. and Patterson, D. R. (1992): Development of the
`Fetal Mouse Palate in an In Vitro Culture System. Poster at Midwest Teratology Association Spring Meeting, U.
`Michigan, May 7-8, 1992.
`
`Patterson, D.R.: GABA uptake inhibition and the pharmacology of tiagabine. Satellite symposium on Tiagabine,
`American Epilepsy Society annual meeting, Seattle, Dec. 6, 1992.
`
`INVITED PRESENTATIONS (32):
`
`Patterson, D. R.: Scientific Session Moderator. Ninth Annual Quad. Branch Meeting of Am. Assoc. for Lab.
`Anim. Sci., Columbia, MO, March l5, l974.
`
`Patterson, D. R., Presiding Officer: Differential Diagnostic Considerations of Infectious Diseases of Laboratory
`Mice. ll8th Annual Meeting of the American Veterinary Medical Association, July 22, l98l.
`
`Patterson, D. R.: Invited speaker: Possible Uniqueness of Male Rat Kidney to Solvent Nephropathy Seminar to
`Dept. of Comparative Medicine, University of Texas Health Science Center, Houston, TX, Dec. l4, l983.
`
`Patterson, D. R.: Preclinical Safety Assessment of New Drugs Entities. Invited speaker to RAPS Drug
`Development Workshop to the members and guests of Regulatory Affairs Professionals Society, Feb. 6-8, 1985 in
`Newport Beach, CA and June 12-14, 1985, Crystal City, VA.
`
`Patterson, D. R.: Invited speaker on Rodents and Other Small Mammals as Models for Evaluation of Drug Toxicity
`in Premature and Term Neonates. Symposium on Animal Models for Evaluation of Drugs for Use in the Mature and
`Immature Newborn, Southwest Foundation for Biomedical Research, San Antonio, TX, Dec. 10, 1985.
`
`Patterson, D.R.: Drug Safety Evaluation at Abbott Laboratories. Keynote Speaker at Ross Laboratories Scientific
`Exchange Conference, Columbus, OH, May 5, 1987.
`
`Patterson, D. R.: Drug Safety and Pharmacology of the NDA Process. Invited speaker at annual meeting of the
`American Association of Pharmaceutical Scientists, Boston, MA, June 7, 1987.
`
`Patterson, D.R.: Drug Safety Evaluation: the Personalization of the IND and NDA Process. Invited speaker at
`annual workshop sponsored by the Regulatory Affairs Professions Society, Washington, DC, June 9-10, 1987.
`
`Patterson, D. R.: Preclinical Safety Assessment Studies Required for NDA (USA). Invited speaker at The
`Japanese-United States Congress of Pharmaceutical Sciences, December 4, 1987, Honolulu, Hawaii.
`
`
`
`
`
`9
`
`INTELGENX 1008
`
`

`
`[D. Reid Patterson, D.V.M., Ph.D.]
`INVITED PRESENTATIONS (continued):
`
`Patterson, D. R., Moderator, Scientific Session of Drusafe West Regional Mee